Amit Sinha
Showing 1–4 of 4 transcripts.
- Goldman Sachs30 min
The Healthcare Outlook: Macro Challenges and Biotech Innovations
Asad Haider, Amit Sinha, Allison Nathan
Following five years of underperformance driven by capital rotation into artificial intelligence and regulatory uncertainty regarding drug pricing, the U.S. healthcare sector is undergoing a structural correction characterized by a declining S&P 500 weighting and a shift in early-stage capital formation toward private markets. Despite these macro headwinds, specific innovation cycles in oral obesity treatments, oncology, and cardiovascular therapeutics are creating idiosyncratic opportunities, particularly within the mid-cap biotech space where investors are beginning to recognize potential for outsized returns on revenue. While large pharmaceutical firms report initial AI-driven cost savings, market participants remain cautious, awaiting tangible earnings improvements before fully re-rating assets in an environment defined by a looming patent cliff and reduced federal research funding.
- Goldman Sachs34 min
Colossal Biosciences’ Ben Lamm sees ‘de-extinction’ as vital to fighting climate change
Ben Lamm, Amit Sinha, George Church
Co-founded by CEO Ben Lamb and geneticist George Church, Colossal Biosciences leverages multiplex CRISPR editing to restore extinct species like the woolly mammoth as functional tools for Arctic climate mitigation and biodiversity preservation. The company has secured $225 million in funding to execute a for-profit model generating revenue through carbon credits and ecological services, while simultaneously advancing spin-off technologies in artificial wombs and human medicine. By reintroducing megafauna to the Arctic, Colossal aims to lower ground temperatures and store carbon, with subsequent targets including the Thylacine and Dodo to address global ecological voids.
- Goldman Sachs22 min
Why We’re In a ‘Golden Age’ of Life Sciences Innovation
With the life sciences sector valued at over $2 trillion and projected to surpass $5 trillion through innovations like mRNA and cell therapy, analysts Allison Nathan and Amit Sinha characterize the current climate as a golden era driven by advanced genetic tools and supportive regulation. Despite a decade-long market correction caused by unsustainable capital surges and increased clinical trial failures, the industry is adapting by shifting toward private capital scaling and downstream investments in companies with experienced management. This structural evolution aims to sustain the development of critical breakthroughs, such as gene therapies for spinal muscular atrophy and immunotherapies for rectal cancer, while navigating complex supply chain and biological challenges.
- Goldman Sachs41 min
Ryan Watts, CEO and Co-Founder of Denali Therapeutics
Founded by CEO Dr. Ryan Watts in 2015, Denali Therapeutics is leveraging proprietary blood-brain barrier technologies and genetic insights to accelerate clinical-stage programs for Alzheimer's, Parkinson's, and ALS. The company is currently initiating pivotal late-stage trials for Parkinson's and Hunter syndrome while prioritizing preventative strategies and shorter-term milestones in lysosomal storage diseases to validate its pipeline. By combining this technical approach with a culture that accepts failure as part of discovery, Denali aims to shift neurodegenerative treatment from late-stage intervention to early disease prevention within the next decade.